Last reviewed · How we verify
NCT06886113: Corvad AMICS
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
NA trial testing Conventional circulatory support in Cardiogenic Shock in 269 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Shenzhen Core Medical Technology CO.,LTD. |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 269 |
| Start date | 1 October 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 15 February 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Conventional circulatory support
- CorVad
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
Sponsor
Shenzhen Core Medical Technology CO.,LTD.
Who can join
Adults 18 to 80, any sex, with Cardiogenic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. An alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. In the acute setting this is difficult but can be done using the CorVad device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation thereby restoring blood flow to the failing organs. The hypothesis of the current study is to reduce mortality and morbidity of patients with cardiogenic shock using the CorVad device. The study will be carried out as a randomized multicenter study where eligible patients will be randomized to receive conventional circulatory support or support with the CorVad device and inotropic support if needed. A total of 269 patients are planned
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06886113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other Shenzhen Core Medical Technology CO.,LTD. trials
Trials by the same sponsor.
- NCT07233876 — DuoCor 2 DOMINATE Study · NA · not yet recruiting
- NCT06646224 — Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock · NA · recruiting
- NCT06878508 — DuoCor Ventricular Assist System Early Feasibility Study · NA · recruiting
- NCT05876000 — Corheart 6 LVAS Study · NA · recruiting
- NCT06373120 — Interventional Ventricular Assist System for PCI in CHIP Patients · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06886113 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Core Medical Technology CO.,LTD.
- Last refreshed: 20 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06886113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing